IL2 and neoplasm: Our results appear to contradict with those of Schardt et al., who reported increased cytotoxicity and the expansion of anti-CMVpp65 CD8pos T cells directed to EGFRpos tumor cells when using an analogous guided-pMHC-staging (GPS) molecule that was equipped with the same IL2 mutein (H16A and F42A) [16].